Security key
98420X103
X4 PHARMACEUTICALS, INC. - Common Stock, par value $0.001 per share (XFOR)
CUSIP: 98420X103
Q1 2023 13F Holders as of 31 Mar 2023
- Security type / class
- Equity / Common Stock, par value $0.001 per share
- Total 13F shares
- 60,979,055
- Total 13F value
- $53,052,409
- Share change
- +1,592,909
- Put/Call ratio
- 288%
- SEC-reported price per share
- $0.87
- Number of holders
- 56
- Value change
- +$698,212
- Number of buys
- 27
- Number of sells
- 13
- Shares outstanding
- 94,372,096
Holder snapshot
7 signals
Open additional details 1 more signal available
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q1 2023
Institutions
56
Top holders
10
XFOR full security history
Ownership snapshot
Full 13F holder table
Newer quarter: Q3 2025
X4 Pharmaceuticals, Inc SEC filings
X4 Pharmaceuticals, Inc company facts
Broader feeds
Reporting periods
Holder history for CUSIP 98420X103
Recent filing periods:
Ownership snapshot
Top reported holders of XFOR - X4 PHARMACEUTICALS, INC. - Common Stock, par value $0.001 per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
Bain Capital Life Science...
Disclosed value leader
Bain Capital Life Science...
Comparable rows
15/15
Latest evidence
31 Dec 2022
13F
Lead comparable stake: 13%
Showing 1-6 of 15 holder rows.
Quick read
Bain Capital Life Sciences Investors, LLC leads the comparable SEC ownership view at 13%.
15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens Bain Capital Life Sciences Investors, LLC's linked filing trail.
Comparable ownership
Top 5
Bain Capital Life Sciences Invest...
13%
NEA Management Company, LLC
12%
ORBIMED ADVISORS LLC
6.2%
AXA S.A.
4.6%
Tri Locum Partners LP
3.9%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| Bain Capital Life Sciences Investors, LLC |
13F
Company
|
13%
|
$12,117,000
12,202,510 shares
|
— | 31 Dec 2022 |
| NEA Management Company, LLC |
13F
Company
|
12%
|
$11,654,635
11,736,793 shares
|
— | 31 Dec 2022 |
| ORBIMED ADVISORS LLC |
13F
Company
|
6.2%
|
$5,777,002
5,817,726 shares
|
— | 31 Dec 2022 |
| AXA S.A. |
13F
Company
|
4.6%
|
$4,331,110
4,361,641 shares
|
— | 31 Dec 2022 |
| Tri Locum Partners LP |
13F
Company
|
3.9%
|
$3,681,000
3,706,517 shares
|
— | 31 Dec 2022 |
| VANGUARD GROUP INC |
13F
Company
|
3.8%
|
$3,555,326
3,580,389 shares
|
— | 31 Dec 2022 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q1 2023
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
56
Shares
60,979,055
Rows available
56
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q1 2023 vs Q1 2026 Across Filers
Q1 2026 holders
2
Q1 2023 holders
56
Holder diff
54
| Investor | Q1 2026 Shares | Q1 2023 Shares | Share Diff | Share Chg % | Q1 2026 value | Q1 2023 value | Value change | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend